查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
帶狀皰疹治療的全球市場:市場規模 - 各給藥途徑，各治療類型，各流通管道，各地區展望，競爭策略，各市場區隔預測(～2032年)
市場調查報告書
商品編碼
1174974

帶狀皰疹治療的全球市場:市場規模 - 各給藥途徑，各治療類型，各流通管道，各地區展望，競爭策略，各市場區隔預測(～2032年)

Herpes Zoster Treatment Market Size- By Route Of Administration, By Treatment Type, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 238 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球帶狀皰疹治療的市場規模，至2032年達到3億2,000萬美元，預計以3.68％的年複合成長率成長。

由於COVID-19影響，醫院和醫療機關非選擇性的治療延期，不過，帶狀皰疹治療市場預計慢慢恢復。

本報告提供全球帶狀皰疹治療市場相關調查，市場動態，市場變數與展望，各給藥途徑、治療類型、流通管道、地區的市場分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球帶狀皰疹治療市場上COVID-19的影響

第5章 市場變數與展望

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球帶狀皰疹治療市場:各給藥途徑(2019年～2032年(100萬美元))

  • 口服
  • 局部

第7章 全球帶狀皰疹治療市場:各治療類型(2019年～2032年(100萬美元))

  • 抗病毒藥物
  • 抗發炎劑
  • 其他

第8章 全球帶狀皰疹治療市場:各流通管道(2019年～2032年(100萬美元))

  • 藥妝店、零售藥局
  • 醫院藥局
  • 線上供應商

第9章 全球帶狀皰疹治療市場:各地區(2019年～2032年(100萬美元))

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲

第10章 企業簡介

  • Abbott Laboratory
    • 企業概要
    • 財務展望
    • 產品概要
    • 最近的開發
  • Bausch Health
  • Camber Pharmaceuticals
  • Cipla Inc.
  • Eli Lilly and Co.
  • GlaxoSmithKline PLC
  • Merck
  • Novaritis AG
  • GoodRx
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
簡介目錄
Product Code: HLCA2221

Global Herpes Zoster Treatment Market Overview:

According to SPER Market Research, the Global Herpes Zoster Treatment Market is estimated to reach USD 0.32 billion by 2032 with a CAGR of 3.68%.

The varicella-zoster virus is the cause of the viral illness known as herpes zoster (shingles). It often starts as a burning, itchy skin rash that spreads to the rest of the body, causing blisters on the back, chest, and face. Pain along the afflicted dermatome is usually the first symptom, which is followed in 2-3 days by an expanded vesicular eruption. Lymph nodes, fever, chills, and headache are among the symptoms. There may also be itching, raised spots on the skin, localised redness, a stabbing or shooting pain, tingling or burning sensation in or beneath the skin, or an upset stomach.

Impact of COVID-19 on the Global Herpes Zoster Treatment Market

In order to prevent cross-contamination, fewer procedures and patients have visited hospitals. This has a detrimental effect on the market for herpes zoster medications. Additionally, a reduction in staff was made to care for patients receiving herpes zoster therapy as a result of the transfer in medical personnel to treat COVID-19-infected individuals. As a result, non-elective procedures were delayed at several hospitals and healthcare institutes. The market for herpes zoster medications, however, is anticipated to gradually rebound after the epidemic.

Scope of the Report:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Route Of Administration, By Treatment Type, By Distribution Channel
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: Abbott Laboratory, Bausch Health, Camber Pharmaceuticals, Cipla Inc., Eli Lilly and Co., GlaxoSmithKline PLC, Merck, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Global Herpes Zoster Treatment Market Segmentation:

  • By Route Of Administration: Based on the Route Of Administration, Global Herpes Zoster Treatment Market is segmented as; Oral and Topical.
  • By Treatment Type: Based on the Treatment Type, Global Herpes Zoster Treatment Market is segmented as; Antiviral Medications, Anti-inflammatory Medications and Other.
  • By Distribution Channel: Based on the Distribution Channel, Global Herpes Zoster Treatment Market is segmented as; Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Provider.
  • By Region: In terms of revenue, North America led the world market for treating herpes zoster and is predicted to maintain that position. This is a result of the presence of important actors throughout the region and the accessibility of cutting-edge healthcare facilities with skilled medical personnel.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Herpes Zoster Treatment Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Herpes Zoster Treatment Market, By Route Of Administration, 2019-2032 (USD Million)

  • 6.1. Oral
  • 6.2. Topical

7. Global Herpes Zoster Treatment Market, By Treatment Type, 2019-2032 (USD Million)

  • 7.1. Antiviral Medication
  • 7.2. Anti-inflammatory Medications
  • 7.3. other

8. Global Herpes Zoster Treatment Market, By Distribution Channel, 2019-2032 (USD Million)

  • 8.1. Drug Stores & Retail Pharmacies
  • 8.2. Hospital Pharmacies
  • 8.3. Online Provider

9. Global Herpes Zoster Treatment Market, By Region, 2019-2032 (USD Million)

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 United Kingdom
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Rest of South America
  • 9.5 Middle East & Africa
    • 9.5.1 Kingdom of Saudi Arabia
    • 9.5.2 United Arab Emirates
    • 9.5.3 Rest of Middle East & Africa

10. Company Profiles

  • 10.1 Abbott Laboratory
    • 10.1.1 Company details
    • 10.1.2 Financial outlook
    • 10.1.3 Product summary
    • 10.1.4 Recent developments
  • 10.2 Bausch Health
    • 10.2.1 Company details
    • 10.2.2 Financial outlook
    • 10.2.3 Product summary
    • 10.2.4 Recent developments
  • 10.3 Camber Pharmaceuticals
    • 10.3.1 Company details
    • 10.3.2 Financial outlook
    • 10.3.3 Product summary
    • 10.3.4 Recent developments
  • 10.4 Cipla Inc.
    • 10.4.1 Company details
    • 10.4.2 Financial outlook
    • 10.4.3 Product summary
    • 10.4.4 Recent developments
  • 10.5 Eli Lilly and Co.
    • 10.5.1 Company details
    • 10.5.2 Financial outlook
    • 10.5.3 Product summary
    • 10.5.4 Recent developments
  • 10.6 GlaxoSmithKline PLC
    • 10.6.1 Company details
    • 10.6.2 Financial outlook
    • 10.6.3 Product summary
    • 10.6.4 Recent developments
  • 10.7 Merck
    • 10.7.1 Company details
    • 10.7.2 Financial outlook
    • 10.7.3 Product summary
    • 10.7.4 Recent developments
  • 10.8 Novaritis AG
    • 10.8.1 Company details
    • 10.8.2 Financial outlook
    • 10.8.3 Product summary
    • 10.8.4 Recent developments
  • 10.9 GoodRx
    • 10.9.1 Company details
    • 10.9.2 Financial outlook
    • 10.9.3 Product summary
    • 10.9.4 Recent developments
  • 10.10 Pfizer Inc.
    • 10.10.1 Company details
    • 10.10.2 Financial outlook
    • 10.10.3 Product summary
    • 10.10.4 Recent developments
  • 10.11 Teva Pharmaceutical Industries Ltd.
    • 10.11.1 Company details
    • 10.11.2 Financial outlook
    • 10.11.3 Product summary
    • 10.11.4 Recent developments